Floatz logo

ryz401

GEP-NET

RayzeBio, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the GEP-NET cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BBB
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 3BB
EUDEMINE INJECTION
University of Maryland, Baltimore
Phase 4BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
Everolimus
RayzeBio, Inc.
Phase 3BB

View all 46 →

Same molecule, other indications

ryz401 is also rated in:

digestive system neuroendocrine neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
carcinoid tumorDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →